Previously submitted to: JMIR Research Protocols (no longer under consideration since Aug 21, 2025)
Date Submitted: Sep 17, 2024
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The effects of valence of TV series on mood and depression: An exploratory randomised pilot trial with a clinical sample
ABSTRACT
Background:
Valence of media such as music and digital media have shown to influence consumers’ mood and course of depression. Yet, we have limited knowledge of how valence of series can influence these states.
Objective:
This trial will test if valence of different series (drama, comedy, action) watched over 10 days influences mood and depression scores of a clinical sample of 45 (15 in each group) depressed Austrian young adults (age 18-35).
Methods:
Participants will be randomised into three groups concerning the valence of three commercial series (drama, comedy, action). In a pre-post-study, we will examine the potential influence of watching these series on mood and depression scores, measured with the Depressions-Angst-Stress-Skalen (DASS21) and Aktuelle Stimmungsskala (ASTS).
Results:
The trial has been funded by Karl Landsteiner University of Health Sciences and Land Niederösterreich and will start in October 2024.
Conclusions:
Results of this trial can provide first insights into practical implications of series consumption and mood for both clinical depression and general mood, which could lead to easy recommendations concerning series consumption.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.